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Abstract
The preferential metastasis of prostate cancer cells to bone disrupts the process of bone remodeling and results in
lesions that cause significant pain and patient morbidity. Although prostate-specific antigen (PSA) is an established
biomarker in prostate cancer, it provides only limited information relating to bone metastases and the treatment of
metastatic bone disease with bisphosphonates or novel noncytotoxic targeted or biological agents that may provide
clinical benefits without affecting PSA levels. As bonemetastases develop, factors derived from bonemetabolism are
released into blood and urine, including N- and C-terminal peptide fragments of type 1 collagen and bone-specific al-
kaline phosphatase, which represent potentially useful biomarkers for monitoring metastatic bone disease. A number
of clinical trials have investigated these bone biomarkers with respect to their diagnostic, prognostic, and predictive
values. Results suggest that higher levels of bone biomarkers are associated with an increased risk of skeletal-related
events and/or death. As a result of these findings, bone biomarkers are now being increasingly used as study end
points, particularly in studies investigating novel agents with putative bone effects. Data from prospective clinical trials
are needed to validate the use of bone biomarkers and to confirm that marker levels provide additional information
beyond traditional methods of response evaluation for patients with metastatic prostate cancer.
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Introduction
In the United States and Europe, an estimated 192,000 and 346,000
new cases of prostate cancer are diagnosed each year, respectively [1,2].
For advanced prostate cancer, the standard first-line treatment is an-
drogen deprivation therapy using medical or surgical castration [3].
Although most patients initially respond to castration therapy, pros-
tate cancer eventually progresses despite castrate levels of androgens
(<50 ng/ml; termed castration-resistant prostate cancer [CRPC]). Early
clinical manifestations of progressive CRPC include a rising prostate-
specific antigen (PSA) concentration and substantial pain in 90%
and 35% patients, respectively [4]. As CRPC progresses, approximately
90% patients will develop bone metastases and 20% will develop soft-
tissue metastases, most commonly in the lung, liver, or lymph nodes
[4,5]. Currently, prostate cancer with bone metastases is not considered
curable [6]. The median survival of patients with bone metastases is
approximately 20 months [7] and is increasing with chemotherapy
and other novel agents. Management of quality of life in this patient
group is therefore especially important and is likely to improve with
the emergence of new bone-specific therapies, such as inhibitors of re-
ceptor activator of nuclear factor κB ligand (RANKL), and the increas-
ing focus on patients with bone metastases in the overall management
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of prostate cancer. Other agents in clinical development for CRPC
that have potential activity against bone metastases include inhibitors
of SRC kinase or endothelin A receptor.
The aim of this review was to discuss the role of bone biomarkers
in the management of CRPC and development and optimization of
bone-targeted therapy.
Biology of Bone Metastases
Bone metastases are most commonly situated in well-vascularized areas
of the skeleton, such as the vertebral column, ribs, skull, and proximal
ends of the long bones [8]. In normal bone, the remodeling process is in
equilibrium; however, the presence of tumor cells disrupts the process,
causing bone lesions that are detectable by radiographic imaging or
radionuclide bone scan. Lesions result from an imbalance between
osteoclast-mediated bone resorption and osteoblast-mediated bone
formation. Osteoclasts adhere to the bone surface and resorb the bone
matrix by secreting proteases and acid, and in turn, osteoblasts secrete
collagen fibrils that become mineralized, eventually forming bone
[9,10]. However, cross talk between tumor cells and the bone micro-
environment causes disequilibrium in the remodeling process, leading
to a pathologic “vicious cycle.” Specifically, tumor cells secrete factors
that stimulate osteoclast-mediated bone destruction, and factors that
were immobilized within the bone matrix are released, stimulating the
growth of cancer cells and promoting further bone destruction (Figure 1)
[11]. On the basis of radiographic appearance, bone lesions are typi-
cally referred to as “osteolytic” (reflecting net bone loss), “osteoblastic”
or “sclerotic” (reflecting bone formation), or “mixed” [12]. In prostate
cancer, bone metastases are primarily osteoblastic; however, high bone
turnover and consequent excess bone resorption are also characteristic
features [13].
Skeletal-Related Events
Because of their high frequency in CRPC, bone metastases are respon-
sible for a considerable proportion of patient morbidity [14], primarily
through complications known as skeletal-related events (SREs). Tumor-
associated bone lacks the structural integrity of normal bone and is
therefore intrinsically weaker, resulting in a high risk of pathologic frac-
ture. Bone metastases can also cause intermittent or constant bone pain.
Metastatic sites in the vertebral columnmay also cause spinal cord/nerve
root compression. Patients with bone metastases often require palliative
radiation therapy or surgery to bone. Unlike other malignancies such as
breast cancer, hypercalcemia is rare among patients with prostate cancer.
SREs significantly reduce health-related quality of life and result in high
medical costs [15], and patients who develop pathologic fractures have
decreased survival compared with patients without fractures [16]. In a
study of 442 men with advanced prostate cancer, approximately one-
third experienced an SRE before study entry, 49% experienced at least
one SREwhile on study, and 31% experienced two or more SREs [17],
highlighting that patients are at high risk of experiencing multiple SREs
and the importance of reducing the occurrence of SREs [18].
Treatment Options for Patients with Bone
Metastatic CRPC
Because progression of prostate cancer to CRPC signifies incurable dis-
ease, the goals of treatment are to reduce symptoms and extend survival.
Figure 1. The vicious cycle of bone metastases (reproduced and adapted from Guise et al. [121], with permission from the American Asso-
ciation forCancerResearch). Theproductionof cytokines andgrowth factorsby tumor cells, particularly parathyroid hormone–relatedpeptide
(PTH-rP), stimulates osteoblasts to produce RANKL, a key mediator of osteoclastogenesis that is inhibited by OPG. In turn, osteoclast-
mediated bone resorption releases growth factors, such as transforming growth factor β, platelet-derived growth factor (PDGF), and insulin-
like growth factors (IGFs), which promote tumor growth [9,10]. Osteoblast and osteoclast activity results in the release of proteins, protein
fragments, or mineral components directly involved in bone structure or metabolism into the blood and urine. Biomarkers of bone formation
include BAP, PICP/PINP, and OC. Biomarkers of bone resorption include CTX/NTX, PYD, and DPD; ICTP; BSP; and TRACP5b.
686 Bone Biomarkers in Prostate Cancer Brown and Sim Neoplasia Vol. 12, No. 9, 2010
Current treatment options therefore include agents that decrease tumor
growth and/or decrease the morbidity of metastatic bone disease.
Chemotherapy
Chemotherapy is used in patients with CRPC who have radiologic
evidence of nodal, bone, or visceral metastases. Docetaxel, an inhibitor
of microtubule function and cell division, became the standard of care
for patients with CRPC after two landmark phase 3 studies that dem-
onstrated a survival benefit in patients with progressive metastatic
CRPC [19–21]. In the TAX327 study, 1006 patients were randomized
to receive docetaxel or mitoxantrone, each combined with low-dose
prednisolone. Compared with the mitoxantrone arm, the docetaxel
arm had longer survival, enhanced quality of life, a lower need for pain
control, and higher rates of objective tumor response and PSA decline
[21]. The survival advantage with docetaxel-based chemotherapy was
confirmed in the Southwest Oncology Group (SWOG) 9916 study,
in which 770 men received mitoxantrone plus prednisone or estramus-
tine phosphate plus docetaxel [20].
Bone-Directed Therapy
Although chemotherapeutic agents such as docetaxel can lead to a re-
duction in bone pain, treatments that specifically target bone disease are
an important component of therapy. Bisphosphonates (BPs), which
inhibit osteoclast-mediated bone resorption at sites of active bone remo-
deling including bone metastases, have become an integral part of man-
aging metastatic bone disease [22]. In patients with advanced CRPC
and bone metastases, placebo-controlled studies have shown that the
BP zoledronic acid significantly reduces the incidence and delays the
onset of SREs [17,23,24]. Zoledronic acid, administered as a 4-mg in-
fusion every 3 to 4 weeks in conjunction with standard anticancer
therapy, is the only BP approved for use in CRPC; however, zoledronic
acid treatment is not recommended in patients with severe renal impair-
ment [25] and it has been associated with osteonecrosis of the jaw [26],
although this is a rare complication and is now known to also occur with
newer therapies that inhibit bone resorption such as denosumab [27].
Improved understanding of the biology of bone metastases has led
to the development of novel bone-specific agents, which, in some cases,
are in advanced clinical trials and approaching registration. These are
likely to have a major effect on the management of metastatic bone dis-
ease in prostate cancer and are considered in detail later in this review.
Systemically administered radiotherapeutic agents (traditionally phos-
phorus 32 and strontium 89) have been used for palliation of skel-
etal metastases. Recently, novel agents that preferentially localize to
osteoblastic metastases have been developed, which combine chelating
agents with radionuclides that have shorter half-lives and lower-energy
particle emissions. In a phase 2 study of patients with CRPC and bone
metastases, radium 223 was well tolerated with minimal myelotoxicity.
Median overall survival was 65.3 weeks for radium 223 compared with
46.4 weeks for placebo (P = .066) [28]. Radium223 is currently in phase
3 trials. Similarly, combination therapy with samarium 153, and doce-
taxel was well tolerated in phase 1 and 2 studies and provided sustained
pain relief [29,30].
Bone Biomarkers in Prostate Cancer
A biomarker is defined as a characteristic that is objectively measured
and evaluated as an indicator of normal biologic processes, pathogenic
processes, or pharmacologic responses to a therapeutic intervention. If
a biomarker is to be used to monitor treatment response, it should be
specific to the relevant disease and correlate closely with aspects of the
disease that influence quality of life and survival. Biomarkers should be
sensitive, have no overlap between untreated and healthy patients, and
show little variation within the general population. Biomarkers should
also be predictive, changing rapidly in response to specific treatments,
and sufficiently different from control values to indicate disease severity
and prognosis. Finally, biomarkers should be robust and accessible, that
is, unaffected by unrelated conditions and reliably quantified in clinical
samples. Although biomarkers can be tissue- or fluid-based, difficulty
in obtaining tissue for direct tumor analysis means fluid-based bio-
markers, such as those found in blood and urine, are most common.
Together, the criteria listed represent an ideal biomarker. Although it
is very unlikely that any clinical biomarker could attain all of these char-
acteristics, biomarkers already play significant roles in clinical practice
and will likely become increasingly important. This is especially true
of prostate cancer, where PSA is already the most commonly used bio-
marker in cancer, and bone biomarkers are showing increasing potential
in clinical management.
The clinical value of PSA, a 34-kDa glycoprotein normally found
almost exclusively in prostate cells and seminal fluid, has been exten-
sively investigated. Because serum PSA levels roughly correlate with
the extent of the disease [31] and can be easily and reproducibly evalu-
ated, PSA has been used as a diagnostic, prognostic, and predictive tool
[32–34]. Importantly, a rise in PSA while a patient is receiving andro-
gen deprivation therapy potentially signals a transition from hormone-
sensitive prostate cancer to CRPC. However, castration levels of serum
testosterone must be demonstrated before castration resistance is con-
firmed. Alternative biomarkers that may identify progression to castra-
tion resistance at an early stage are currently under investigation [35].
PSA, however, has several restrictions as a biomarker [36]. Its use in
monitoring CRPC is limited, for example, in the context of novel non-
cytotoxic treatments that may have little effect on PSA levels [37,38].
Importantly, PSA levels do not provide accurate information regarding
the extent of bonemetastasis or bone-specific effects of treatment,mean-
ing that alternative biomarkers are required for this specific purpose.
Biomarkers of Bone Turnover
During bone turnover, active bone resorption and formation results
in the release of bone-associated proteins, protein fragments, or mineral
components into the blood and urine, which represents a rich source of
potential biomarkers (Table 1) [13,39–58]. In metastatic bone disease,
the disruption of normal bone turnover leads to abnormally high levels
of these biomarkers. Bone biomarkers are usually classified as either
“formation markers” or “resorption markers” depending on which side
of the process they arise.
Biomarkers of Bone Formation
Type 1 collagen constitutes approximately 90% of the bone matrix
and is synthesized as a procollagen that has amino-terminal (PINP) and
carboxy-terminal (PICP) propeptides. Before fibril formation, PINP
and PICP are cleaved off and released into the circulation in equimolar
amounts and are cleared by the liver. Blood concentrations of PINP
and PICP are indicators of ongoing type 1 collagen synthesis and early
bone formation, and concentrations increase during osteoblast prolifer-
ation [59,60]. Bone-specific alkaline phosphatase (BAP) is a marker of
the middle stage of bone formation, appearing during the matrix matu-
ration phase [60]. Alkaline phosphatase isoforms originate mainly from
liver and bone, with the bone isoform accounting for 40% to 50% in
normal adults [61]. The bone isoform is a specific marker for osteogen-
esis, and concentrations are elevated in metastatic bone disease, Paget
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disease, and osteomalacia [39]. Osteocalcin (OC) is a noncollagenous
marker of late bone formation, appearing during the mineralization
phase, that is produced by osteoblasts and is also detectable in blood
[60]. Osteoprotegerin (OPG) is produced by osteoblast and stromal
cells and binds to RANKL, preventing interaction with RANK and
thereby inhibiting osteoclastogenesis and bone resorption [62]. Bone
metastases from prostate cancer stimulate a profound elevation in OPG
and decrease in the RANKL/OPG ratio [63].
Biomarkers of Bone Resorption
Several markers of bone resorption are degradation products of
type 1 collagen. For example, N- and C-terminal peptide fragments of
type 1 collagen (NTX and CTX) are released into the circulation and
urine during osteoclast-mediated bone resorption [11]. The NTX
peptide exists in α1 and α2 isoforms, with the latter primarily derived
from bone. Similarly, CTX exists asα and β isoforms, with the β isoform
found primarily derived from bone [39]. Strands of type 1 collagen are
connected between lysine and hydroxylysine residues by chemical cross-
links, including pyridinoline (PYD) and deoxypyridinoline (DPD),
which mechanically stabilize the collagen molecule by bridging several
collagen peptides. During collagen degradation, PYD and DPD are
released at a ratio of approximately 3:1 and are detectable in the circu-
lation and urine [64], with urinary excretion closelymirroring the rate of
bone resorption. Although DPD is relatively specific for bone, PYD is
also found in articular cartilage, ligaments, and tendons, although bone
is the main reservoir and has a higher turnover than connective tissues.
C-terminal cross-linked telopeptides (ICTPs) are also released into the
circulation after enzymatic degradation of type 1 collagen by metallo-
proteinases. These are distinct to CTX peptides, which are generated
through a distinct collagenolytic pathway [65].
Bone sialoprotein (BSP) is a noncollagenous glycoprotein found
within the bone matrix that is produced by osteoclasts and may pro-
mote osteoclast attachment to bone and osteoclastogenesis [39,66].
In patients with localized prostate cancer, high BSP expression is asso-
ciated with biochemical disease progression [67]. BSP activity is regu-
lated by tartrate-resistant acid phosphatase type 5b (TRACP5b) [39],
which itself is a marker of osteoclastic activity and bone resorption
secreted by osteoclasts after attaching to bone [68]. After entering the
circulation, TRACP5b is inactivated and degraded, so that levels of
catalytically active enzyme reflect bone-resorptive activity [39].
Clinical Value of Bone Biomarkers
Bone biomarkers complement information derived from radiographic
assessment and can be measured easily, serially, relatively noninvasively,
Table 1. Bone Biomarkers (Adapted from Seibel [13] and Coleman et al. [39]).
Marker Tissue of Origin Specimen Evaluation Method Known Limitations
Markers of bone formation
PICP/PINP Bone; soft tissue; skin Serum RIA, ELISA [40–42] Concentrations may increase
with increased turnover
of nonskeletal collagen
BAP Bone Serum Colorimetric,
electrophoresis,
precipitation,
IRMA, EIA [43,44]
Significant cross-reactivity
(±15%) with liver alkaline
phosphatase may occur
during assaying
OC Bone; platelets Serum RIA, IRMA, ELISA [45] Not a pure marker of
osteoblast function
because some OC
may be derived from
bone resorption
Detection may be confounded
by high lipid levels that
bind OC [45]
Measurement is complicated
by the presence of several
immunoreactive fragments
and a lack of standardization
in methodology
Markers of bone resorption
PYD Bone; cartilage; tendon;
blood vessels
Urine, serum HPLC, ELISA [46,47] –
DPD Bone; dentin Urine, serum HPLC, ELISA [47,48] –
CTX All tissues containing
type 1 collagen
Urine (α and β),
serum (β)
ELISA, RIA [49,50] Limited assay precision at
low urinary concentrations
NTX All tissues containing
type 1 collagen
Urine, serum ELISA, CLIA, RIA [51,52] –
ICTP Bone; skin Serum RIA [53] Might be derived from newly
synthesized collagen
BSP Bone; dentin;
hypertrophic
cartilage
Serum RIA, ELISA [54] May reflect cell-related processes
rather than the release of
degradation products
Binds to complement factor H
and this complex must be disrupted
for accurate measurement [55]
OPG Bone; cardiovascular,
gastrointestinal and
neurologic tissue
Plasma, serum ELISA [56] –
TRACP5b Bone; blood Plasma, serum Colorimetry, RIA, ELISA [57,58] –
CLIA indicates chemiluminescent assay; ELISA, enzyme-linked immunosorbent assay; HPLC, high-performance liquid chromatography; IRMA, immunoradiometric assay; RIA, radioimmunoassay.
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and inexpensively. Because changes in bone biomarkers occur rapidly,
they provide information on the status of bone metastases. By contrast,
radiographic methods report accumulated effects; therefore, response to
treatment may not become evident for several months. Samples for
bone marker analysis are generally sent to laboratories; however, there
is increasing interest in developing point-of-care devices to enable clin-
ical teams to make more rational management decisions at the time of
patient visit.
The diagnostic, prognostic, and predictive values of bone biomar-
kers have been assessed in several clinical studies.
Bone Biomarkers in Diagnosis
In retrospective studies, levels of bone biomarkers have been found
to correlate with the presence of bone metastases, with higher levels
of BAP, PINP, PICP, and urinary CTX indicating an increased extent
of bone disease [60,69,70]. PINP levels have also been shown to be
significantly higher in patients with bone metastases than in patients
without metastases or with lymph node metastases only [71,72], and
in a separate study, preliminary analyses suggested that CTX most
sensitively reflected accelerated bone resorption induced by bone me-
tastases [73]. However, it is important to note that these were not
prospective studies and the use of bone biomarkers in screening or
diagnosing bone progression remains unvalidated.
Prognostic Value of Bone Biomarkers
The prognosis associated with high levels of bone biomarkers in clini-
cal trials of patients with CRPC and metastatic bone disease has been
analyzed retrospectively. In a study including 117 patients with prostate
cancer, of which 44 had bone metastases, survival was significantly
shorter in patients who had high concentrations of PINP, BAP, total al-
kaline phosphatase, OPG, NTX, TRACPb5, and CTX than in patients
with lower concentrations [74]. In placebo-treated patients with either
metastatic CRPC or non–small cell lung cancer enrolled in two phase 3
trials of zoledronic acid, higher levels of urinary NTX (uNTX) and BAP,
both at baseline and on study, were associated with an increased risk of
SREs and death than low uNTX levels, and uNTX was a stronger prog-
nostic indicator of negative outcome than BAP [75]. In an analysis of
data from a randomized trial, zoledronic acid–treated patients with
CRPC and bone metastases who had high uNTX levels at baseline or
on study had a 5.72-fold increased risk of death than patients with low
levels (P < .001) [76]. In a separate analysis of this patient cohort, serum
BAP significantly correlated with uNTX (correlation coefficient = 0.674,
95% confidence interval [CI] = 0.628-0.715, P < .0001). Furthermore,
an elevated level of serum BAP but not uNTX was independently asso-
ciated with a shorter overall survival after controlling for other variables
[77]. In a separate study of patients with CRPC receiving zoledronic acid,
elevated uNTX, serum PSA, and performance status were all indepen-
dent prognostic factors for overall survival. In patients with uNTX with
20 nmol/mM creatinine or higher or less than 20 nmol/mM creatinine,
median overall survival was 12 months (95% CI = 10-16 months) and
25 months (95% CI = 21-34 months), respectively [7]. In another study,
baseline PINP, BAP, and CTX levels were all elevated in patients with
metastatic prostate cancer, but only PINP was an independent predictor
of survival [78]. Similarly, in a study by the same group, serum levels of
PINP, BAP, and CTX measured serially were higher in men with meta-
static CRPC compared with healthy men, and in a univariate analy-
sis, each marker was significantly associated with reduced survival at
6 months; however, in a multivariate analysis, only high serum PINP
was significantly associated with reduced survival [79].
Predictive Value of Bone Markers
The effects of zoledronic acid on bone biomarkers and their relation-
ship with clinical outcome have been investigated retrospectively using
data from large, randomized, double-blind, phase 3 trials. In the subset
of patients with CRPC, normalization of uNTX after 3 months of
treatment with zoledronic acid, compared with persistent elevation
of uNTX, correlated with improved overall survival, with the risk of
death reduced by 59% (relative risk = 0.41; 95% CI = 0.29-0.59; P <
.0001). In addition, SRE-free survival was increased by 49% (P =
.0009). Regardless of baseline uNTX level, a 40% reduction in uNTX
at 3 months resulted in a significant reduction in the risk of death [80].
In a smaller study of 71 patients with bone metastases from various
cancers who received zoledronic acid, patients with an initial elevation
in NTX with treatment had a significantly higher rate of bone disease
progression compared with those who had an initial decline (67% vs
19%, P = .001) [81]. In a study of 117 men with CRPC (56 with an
SRE and 61 without), serial measurements of BAP, PINP, NTX, ICTP,
CTX, and PSA were taken at baseline and every 12 weeks for 60 weeks
after administration of zoledronic acid. Except for ICTP, bone markers
decreased to 20% to 80% of baseline values at week 12, and except for
NTX, declines were higher in the non-SRE group. At all time points,
higher and increasing concentrations of bone markers were observed in
patients with SREs than those without. The study showed that changes
in PINP, ICTP, CTX, and NTX during treatment were significant pre-
dictors of SRE, although aftermultivariate analysis, onlyNTX remained
independently predictive [82,83].
The Role of Bone Biomarkers in the Development
of Novel Therapies
Although bone biomarkers are not yet in use for routine clinical man-
agement of CRPC, they are well established as surrogate end points
in phase 1/2 studies of new bone-targeted therapies (Tables 2 and
3) [84–97]. In phase 3 trials, SRE measurements remain the criterion
standard for assessing efficacy; however, studies have alsomeasured bone
biomarkers, providing supportive data for correlative analyses.
Denosumab
RANKL, together with its receptor, RANK, and the endogenous
soluble RANKL inhibitor, OPG, play direct and essential roles in the
formation, function, and survival of osteoclasts. Denosumab, a fully
human monoclonal antibody against RANKL, has been shown to in-
hibit osteoclast-mediated bone resorption [96]. A phase 2 trial of deno-
sumab was performed in patients with solid tumors (including prostate
cancer) and bone metastases who had elevated uNTX levels despite on-
going BP therapy. In the prostate cancer subset, bone resorption was
suppressed in a higher percentage of patients treated with denosumab
compared with zoledronic acid, as demonstrated by the number of
patients with uNTX levels less than 50 nM (22 [69%] of 32 vs 3
[19%] of 16, respectively) and the median percentage reduction in
uNTX levels from baseline (84% vs 32%, respectively; Figure 2A). In
addition, a lower proportion of patients treated with denosumab than
zoledronic acid experienced an on-study SRE (1 [3%] of 33 vs 3 [19%]
of 16, respectively) [97]. Bone biomarkers may therefore be valuable
in individual patients for determining when to change to a different
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bone-targeted therapy. Primary data from a randomized phase 3 trial of
denosumab in patients with metastatic CRPC are expected in 2010,
with early reports indicating that compared with zoledronic acid, deno-
sumab significantly delayed time to first SRE and significantly reduced
first-and-subsequent SREs [98].
SRC Inhibitors
SRC and SRC family kinases have a key role in tumor cell processes,
such as growth, invasion, and metastasis, in addition to normal and
pathologic bone activity. SRC also acts in concert with the macro-
phage colony-stimulating factor receptor (FMS) to potentiate osteoclast
Table 2. Effects of Novel Agents on Bone Markers.
Agent Patient Population N Treatment and Dosage Treatment Efficacy Bone Biomarker Effects
Atrasentan Metastatic
CRPC [84,85]
288 Atrasentan 2.5 or
10 mg QD vs placebo
Median time to progression:
183 days (10 mg atrasentan)
vs 137 days (placebo); P = .13
No significant decrease
from baseline with atrasentan
Median time to PSA progression:
155 days (10 mg atrasentan) vs
71 days (placebo); P = .002
Smaller elevations in NTX,
CTX and DPD from
baseline with 10 mg
atrasentan vs placebo
Metastatic
CRPC [86]
809 Atrasentan 10 mg
QD vs placebo
No reduction in risk of disease
progression
Mean BAP increased by
13.2 ng/ml (atrasentan)
vs 33.9 ng/ml (placebo); P < .001
Longer time to PSA progression
with atrasentan
Median time to BAP progression:
505 days (atrasentan) vs 254 days
(placebo); P < .01
Metastatic prostate
cancer [87]
44 Atrasentan 10 mg
QD (n = 22) or
atrasentan 10 mg
QD plus zoledronic
acid Q4W (n = 22)
SD (no PSA or radiographic
progression) at 12 weeks in
3/22 (14%) in both arms
No significant difference in BAP
changes between arms
Mean serum NTX increased by
32.4% ± 14.5% (atrasentan), decreased by
34.4% ± 6.9% (combination); P < .001
Metastatic
CRPC [88]
31 Atrasentan 10 mg QD
plus docetaxel 60, 70
or 75 mg/m2 Q21D
PR in 2/13 (15%); unconfirmed
SD in 10/13 (77%)
Median BAP decreased from 18 μg/l
to 12.2 μg/l (P = .0003)
PSA response (>30% decline from
baseline within 3 months) in 35%
Median NTX value decreased
from 12.8 nM BCE to 10.9 nM
BCE; P = .04
Zibotentan Metastatic
CRPC [89]
16 Zibotentan 10-200 mg
QD (escalating doses)
No objective responses Considerable intrapatient and
interpatient variability in BAP,
PINP, CTX, and NTX
Dasatinib Metastatic
CRPC [90]
47 Dasatinib 100 mg BID
(n = 25) and 70 mg
BID (n = 22)
Lack of progression by RECIST
and bone scan in 20/47 (43%)
patients at week 12 and 9/47
(19%) patients at week 24
51% of patients had a ≥40%
reduction in urine NTX and 60%
had a reduction in BAP
Metastatic
CRPC [91]
48 Dasatinib 100 mg QD 12 patients (25%) had disease
control (PSA response; SD,
CR or PR by RECIST;
improved bone scan)
51% of patients had a ≥40%
reduction in urine NTX and
59% had a reduction in BAP
Metastatic
CRPC [92]
46 Dasatinib 50-120 mg
QD and docetaxel 65
or 75 mg/m2 Q21D
(n = 46)
PR in 17/30 patients (57%);
SD ≥18 weeks in 5/30 (17%)
49% of patients had a ≥35%
decrease in urine NTX and
73% had a reduction in BAPReduction in size and number of bone
lesions at ≥6 weeks in 13/45 (29%)
PSA response (>50% decline sustained
for ≥6 weeks) in 26/44 (59%)
Saracatinib Healthy
volunteers [93]
59 Single-dose saracatinib
60-250 mg, followed
7-10 days later with
daily doses for
10-14 days
N/A Reduction from baseline in
serum CTX (88%), uNTX (67%)
and TRACPb5 (11%) with 250 mg
(maximum tolerated dose)
Advanced
CRPC [94]
28 Saracatinib
175 mg QD
Transient PSA
reduction in
five patients
Not reported
Denosumab Solid tumors and
bone metastases,
with or without
prior BP therapy [95]
366 IV BP Q4W (n = 80);
denosumab 30 mg QW4
(n = 42), 120 mg QW4
(n = 42), 180 mg QW4
(n = 81), 60 mg Q12W
(n = 42) or 180 mg
Q12W (n = 79)
N/A Median uNTX decrease
of 75% (BP-naive) or
80% (previous IV therapy);
median TRACP5b decrease of 73%
Solid tumors and
bone metastases,
with prior BP
therapy (subanalysis) [96]
111 IV BP Q4W (n = 37);
denosumab 180 mg
Q12W (n = 36) or
180 mg Q4W (n = 38)
N/A Median uNTX decrease of 78%;
reductions in serum CTX, PINP,
TRACP5b, BAP, and OC
Prostate cancer and bone
metastases, with
previous BP therapy
(subanalysis) [97]
50 IV BP Q4W (n = 17);
denosumab 180 mg
Q4W (n = 17) or
180 mg Q12W (n = 16)
N/A 69% of patients had uNTX <50 nM;
median uNTX decrease of 84%
BCE, bone collagen equivalent; BID, twice daily; CR, complete response; IV, intravenous; N/A, not applicable; PR, partial response; Q4W, every 4 weeks; Q12W, every 12 weeks; Q21D, every 21 days;
QD, once daily; RECIST, response criteria in solid tumors; SD, stable disease.
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activation. Dasatinib is a potent inhibitor of SRC plus SRC family
kinases and FMS, which also has activity against platelet-derived growth
factor receptor, c-KIT and ABL [99,100]. In vitro studies have found
that dasatinib has antiosteoclast activity in addition to antitumor and
antimetastatic activities against prostate cancer cell lines [101–103].
In two clinical studies in metastatic CRPC, dasatinib treatment has re-
sulted in decreased levels of bone markers. In a study of dasatinib
monotherapy administered in a twice-daily schedule, a 40% decrease
Figure 2. Modulation of NTX in patients with metastatic CRPC after treatment with novel therapies. (A) Percentage change in uNTX during
weeks 1 to 25 in patients treated with denosumab or zoledronic acid, demonstrating rapid denosumab-induced suppression of bone re-
sorption (reprinted from Fizazi et al. [97], Copyright 2009, with permission from Elsevier). (B) Waterfall plot of maximal percentage change in
uNTX from baseline in patients treated with 70 or 100 mg of dasatinib twice daily. Of 41 patients, 33 (80%) had a decrease in uNTX while on
study (reproduced and adapted from Yu et al. [90], with permission from the American Association for Cancer Research). (C) Percentage
change in uNTX during weeks 1 to 12 in patients treated with atrasentan or atrasentan plus zoledronic acid. Mean serum NTX increased by
32.4% ± 14.5% with atrasentan and decreased by 34.4% ± 6.9% in the combination group (P < .001; reproduced and adapted from
Michaelson et al. [87], with permission from John Wiley and Sons).
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in uNTX or higher or a decrease from baseline in BAP were observed
in 51% (21/41) and 60% (24/40) patients, respectively (Figure 2B)
[90], and similar results were observed in patients who received dasa-
tinib once daily [91]. In a phase 1/2 dose-finding study of patients
dasatinib plus docetaxel, 49% (18/37) had a 35% decrease in uNTX
or higher and 73% (25/34) had a decrease in BAP from baseline [92].
The potential clinical benefits of combination treatment with dasatinib
and docetaxel in patients with CRPC are currently being evaluated in a
phase 3 trial.
Saracatinib (AZD0530), a highly selective oral SRC/ABL kinase in-
hibitor, inhibits osteoclast-mediated bone resorption and the growth
of prostate cancer cells in vitro and in vivo [104,105]. In a healthy vol-
unteer study, large decreases of serumCTX and uNTXwere observed in
response to daily dosing during a 14-day period. After treatment was
stopped, there was a gradual return toward pretreatment levels, although
both markers were still significantly reduced compared with baseline
12 days after the final dose [93].
Endothelin Inhibitors
Endothelin 1 is normally expressed in the prostate epithelium. Pa-
tients with metastatic prostate cancer have elevated levels of plasma
endothelin 1 compared with patients with organ-confined cancer. Acti-
vation of endothelin A, the receptor for endothelin 1, is thought to pro-
mote the osteoblastic activity characteristic of prostate cancer bone
metastases [106]. Atrasentan, a highly selective endothelin A receptor
inhibitor, has antiosteoblast and antitumor activity in vitro [107]. In a
phase 2 study of men with metastatic CRPC, significantly lower serum
NTX levels were observed after treatment with atrasentan plus zoledro-
nic acid compared with atrasentan alone (P < .001; Figure 2C ). Reduc-
tions in serum BAP levels were not significantly different between the
groups, and no objective responses were observed in either group [87]. A
phase 3 study comparing atrasentan with placebo in men with meta-
static CRPC was closed early because of an excess of early progression,
mainly on bone scan, although an analysis of the 809 patients accrued
demonstrated a nonsignificant trend toward increased time to progres-
sion in favor of atrasentan. In addition, at the final assessment, the mean
increase inBAP frombaseline was 13.2 ng/mlwith atrasentan compared
with 33.9 ng/ml with placebo [86]. In a phase 1/2 study with atrasentan
plus docetaxel, serumNTX and BAP levels decreased significantly com-
pared with baseline (BAP: P = .0003; NTX: P = .04) [88]. An ongoing
phase 3 study is comparing the survival of patients with CRPC and bone
metastases treated with docetaxel plus atrasentan with patients treated
with docetaxel alone.
In a phase 1 study of zibotentan (ZD4054), an alternative endothelin
A receptor antagonist, bonemarker assessment of BAP, PINP, CTX, and
NTX demonstrated considerable intrapatient and interpatient variabil-
ity, and because of the small number of patients (n = 16), it was im-
possible to make any definitive conclusions [89]. In a randomized
phase 2 trial, although there was no significant difference in progression-
free survival, ZD4054 improved overall survival. Phase 2 results regard-
ing the effects of zibotentan on bone metastases, however, are yet to be
reported [108]. A large phase 3 trial (Enthuse M1C) is currently assessing
the safety and efficacy of zibotentan in combination with docetaxel in pa-
tients with metastatic CRPC.
Limitations of Bone Biomarkers
Because of the substantive ongoing research into whether bone bio-
marker levels can guide treatment decisions for patients with metastatic
CRPC, it is important that any potential limitations are considered.
For example, bone remodeling follows a diurnal rhythm and may
change with the season of the year, posture, exercise, and extremes
of diet. In addition, all bone biomarkers follow a circadian rhythm,
with highest levels in the early morning. However, circadian variations
with PINP and PICP are negligible, and the longer half-life of BAP
makes it less sensitive to circadian variation [61]. With other markers
of bone formation and resorption, day-to-day variations of approxi-
mately 10% or 20%, respectively, have been observed, which can be
reduced by consistency in sampling times. NTX, for example, is usu-
ally assessed on the second voided urine sample of the day.
Bone marker levels can also be affected by concurrent disease. For
example, because BAP is cleared by the liver and NTX, CTX, PYD,
and DPD are cleared by the kidneys, conditions that affect liver or renal
function can influence marker concentrations [109]. Similarly, because
biomarker levels are often normalized with respect to urine creatinine,
increased excretion of urine creatinine due to renal damage can affect
the results of urinary assays. After fracture, marker concentrations in-
crease by 20% to 60% and remain high for 6 months or longer, whereas
with prolonged bed rest, markers may increase by 40% to 50%. Patterns
of change vary between markers. Because the process of resorption is
quicker, levels of resorption markers decrease faster than markers of
formation (in 2-12 weeks compared with 3-6 months, respectively).
Well-validated assays for assessment of bone biomarkers are now avail-
able, with typical intra-assay and interassay variations of less than 10%
[39,109].
Discovery of Novel Bone Biomarkers to Predict
Bone Metastases
The biomarkers discussed here are already proving valuable in develop-
ing new agents and have the potential to provide useful information in
managing the skeletal complications of metastatic prostate cancer.
However, they cannot predict the individual risk of developing meta-
static bone disease; therefore, alternative markers, perhaps in association
with PSA, are required. Some current approaches are discussed below.
Proteomics
Proteomics presents an exciting opportunity in novel biomarker
discovery and has the advantage of examining functional end units
(proteins) [110]. In biological fluids, challenges lie in the large dy-
namic range of protein concentrations and the dominance of a small
number of abundant proteins. To address this, biomarker discovery
generally incorporates prefractionation and/or multidimensional ap-
proaches [111].
Proteomic approaches remain relatively unexploited in bone me-
tastasis [112], with only a few studies reported in prostate cancer
[113,114] and multiple myeloma [115]. Using serum from patients
with advanced prostate cancer, the clinical utility of surface-enhanced
laser desorption/ionization time-of-flight mass spectrometry (SELDI-
TOFMS) to identify serum biomarker patterns associated with prostate
cancer progression was investigated. A specific biomarker profile cap-
tured with SELDI-TOF MS was associated with biochemical relapse
and was prognostic for long-term survival independent of clinical PSA
status [113]. Similarly, SELDI-TOF MS profiling identified a group
of serum amyloid A proteins that predominated in the spectra ob-
tained from patients with prostate cancer and bone metastases [114].
These provide a proof of principle that proteomic profiling has potential
for the discovery of novel biomarkers associated with prostate cancer
bone metastases.
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Circulating Tumor Cells
Circulating tumor cells (CTCs) provide a fluid-based biomarker
that is being investigated as a potential prognostic marker in metastatic
CRPC. CTCs are shed from either the primary tumor or the metastases
and circulate in peripheral blood. Patients with bone metastases have
higher CTC numbers than patients with soft-tissue metastases
[116,117]. In a study of 120 patients with progressive CRPC, higher
baseline CTC numbers were strongly associated with reduced survival
[116]. Posttreatment CTC numbers can also predict survival. In a pro-
spective study of 231 patients with metastatic CRPC, CTC number at
various time points up to 20 weeks after treatment was a stronger
independent predictor of overall survival than PSA reduction [118].
Similarly, in patients with metastatic CRPC receiving first-line chemo-
therapy, although high CTC number and PSA before treatment were
both associated with increased risk of death, increases in CTC number
after treatment were more strongly associated with risk of death than
increases in PSA [119]. As a result, the US Food and Drug Adminis-
tration has approved assessment of CTC using the CellSearch assay for
clinical use in monitoring treatment response and predicting survival
in prostate, breast, and colorectal cancers [118]. Assays of molecular
markers expressed within CTCsmay be similarly predictive of response.
A study quantifying PSA and human kallikrein 2 messenger RNA to
determine the CTC level in 76 patients with CRPC produced results
comparable with the CellSearch assay [117]. However, one limitation
of using CTC count as a biomarker and a source of data for correlative
studies in CRPC is that levels of detectable cells are low in the preche-
motherapy setting [120]. Prospective measurement of CTC number in
randomized phase 3 trials is warranted to assess how changes in CTC
number can be used to guide the choice of treatment.
Conclusions
In patients with CRPC, bone metastases cause SREs that are respon-
sible for substantial morbidity, and assessing bone health is an impor-
tant aspect of clinical monitoring. PSA is the most widely used and
best-characterized biomarker in CRPC; however, it does not provide
accurate information regarding the extent of bone metastasis. Studies
of patients with bone metastases have found an association between
levels of bone biomarkers, both at baseline and during treatment,
and long-term outcomes such as SREs and survival. As a result, bone
biomarkers are increasingly recognized as potential surrogate end points.
Although the most recent Prostate Cancer Working Group guidelines
do not include bone biomarkers as validated end points for clinical trials
of CRPC, various data suggest that bone biomarkers provide important
information regarding effects of treatment on bone metastases. In par-
ticular, the correlation between bone biomarkers and patient outcomes
in BP trials suggest that changes in biomarker levels may indicate treat-
ment failure and/or the need for more aggressive treatment. Further-
more, recent studies with noncytotoxic targeted agents suggest bone
effects and other clinical benefits may occur independent of changes
in PSA level. However, the suggestion that bone biomarkers provide ad-
ditional predictive information beyond traditional assessments requires
further investigation and validation in prospective trials. In addition, it
should be noted that diurnal and day-to-day variability occurs in bone
biomarker levels, and assay results can vary considerably between labo-
ratories, even if they use identical methodology, meaning that stringent
standardization will be needed before assessment is incorporated into
clinical practice. Overall, available data suggest that bone biomarkers
hold future promise for monitoring and optimizing therapies targeted
to the bone microenvironment.
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